Interestingly, converse depletion of CCL2 led to a decrease in tumor size and TAM recruitment only in the background of GNA13 loss, but not in GNA13 wild-type tumors, proposing pharmaceutical targeting of CCL2 in GNA13-mutant cancers as a possible therapeutic intervention to be further investigated. This evidence concerns the gene GNA13 and neoplasm.